EarningsQ2 2026 Earnings Report
WILLF Q2 2026 EPS Results
Actual EPS$0.97
Consensus EPS$0.95
Beat/MissBeat by +$0.02
One Year Ago EPS$0.82
WILLF Q2 2026 Revenue Results
Actual Revenue$1.97B
Expected Revenue$965.83M
Beat/MissBeat by +$1.00B
YoY Revenue Growth+15.13%
Earnings Announcement Details
QuarterQ2 2026
Date08/11/2026
TimeDuring Market Hours
Conference CallTuesday, August 11, 2026
WILLF Upcoming Earnings
Demant's next earnings date is estimated for February 9, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
WILLF Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a largely positive operational and financial picture: strong top-line growth (15% reported), margin expansion, robust cash generation, deleveraging progress, a successful product (Zeal) and a new flagship (Reveal) with promising technology. Challenges include elevated special items and integration costs, FX headwinds, weakness in China, managed-care softness in the U.S., and uncertainty around competitive launches. On balance, the positive growth, margin improvement and upgraded guidance outweigh the headwinds.Company Guidance
Strong Reported Revenue Growth
Reported revenue grew 15% in H1 2026 driven by 7% organic growth, 10% acquisitive growth (predominantly KIND) and a -3% FX headwind.
Upgraded Full-Year Outlook
Management upgraded 2026 guidance to 6%–7% organic revenue growth and EBIT before special items of DKK 4.4bn–4.8bn based on H1 momentum.
Gross Profit and Margin Expansion
Gross profit increased 17% to just shy of DKK 10bn in H1; gross margin expanded by 1.1 percentage points versus prior year, above expectations.
EBIT Performance and Underlying Margin Improvement
EBIT before special items was DKK 2.134bn (16.5% margin) in H1, reflecting 19% growth in local currencies; excluding certain FX and one-off items underlying EBIT margin expanded ~0.6ppt.
Strong Cash Generation and Deleveraging
Operating cash flow was DKK 1.6bn (+6% vs H1 2025); net cash inflow from acquisitions/divestments DKK 91m; leverage has fallen from post-KIND peak to 3.0 with target gearing slightly above 2–2.5 by end-2026.
Hearing Aids: Product-Led Acceleration (Oticon Zeal)
Hearing Aids accelerated, with the Zeal rollout driving a 10% growth in Q2 and strong double-digit growth in North America; management also reported a +1% ASP improvement in Q2.
New Flagship Launch (Oticon Reveal) — Technology Upgrade
Introduced Oticon Reveal with a 'Dual AI' system, improved feedback prevention, new connectivity platform and power-efficient single-chip design; management cites significant improvements in signal-to-noise and speech intelligibility from trials.
Hearing Care: Acquisition-Led and Organic Growth
Hearing Care recorded impressive performance in Q2: KIND delivered 31% growth (23ppt from acquisitions) and the business achieved 8% organic growth in the quarter, supporting scale and profit.
Diagnostics Recovery
Diagnostics returned to solid growth with 9% growth in Q2, led by instrument sales and broad-based recovery in the U.K., U.S. and Canada.
Cost-Savings Progress and Increased Efficiency Targets
Cost-saving initiatives are ahead of plan; program contribution raised to DKK 300m (from DKK 250m) and expected EBIT contribution from KIND increased to DKK 325m (from DKK 300m).
WILLF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed